Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

141. Prucalopride for the treatment of chronic constipation in women

Prucalopride for the treatment of chronic constipation in women Prucalopride for the treatment of chronic constipation in women Prucalopride for the treatment of chronic constipation in women National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Prucalopride (...) for the treatment of chronic constipation in women. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 211. 2010 Authors' conclusions Prucalopride is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered

2010 Health Technology Assessment (HTA) Database.

142. LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial

LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial Speed C, Heaven B, Adamson A, Bond J, Corbett S, Lake AA, May C, Vanoli A, McMeekin P, Moynihan P (...) , Rubin G, Steen IN, McColl E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Speed C, Heaven B, Adamson A, Bond J, Corbett S, Lake AA, May C, Vanoli A, McMeekin P, Moynihan P, Rubin G, Steen IN, McColl E. LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial. Health

2010 Health Technology Assessment (HTA) Database.

143. Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation

Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation Belsey JD, Geraint M, Dixon TA CRD summary This review concluded that polyethylene glycol was more effective than lactulose for the treatment of adults with non-organic constipation. Overall, the findings (...) of the review appear valid, but the risk of missing data and lack of detail regarding the review methods made the reliability unclear. Authors' objectives To compare the efficacy of polyethylene glycol (PEG) versus placebo or active comparators for the treatment of non-organic constipation in adults. Searching MEDLINE, EMBASE, CINAHL and Cochrane Central Register of Controlled Trials (CENTRAL) databases and Google Scholar were searched for studies published in peer-reviewed journals from January 1970

2010 DARE.

144. The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK

The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK Taylor RR, Guest JF Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to estimate the cost-effectiveness of macrogol 3350, compared with lactulose, for the treatment of chronic constipation in adults. The authors concluded that macrogol 3350 was cost-effective. The methods and the reporting of the results were good

2010 NHS Economic Evaluation Database.

145. Methylnaltrexone (Relistor) for opioid-induced constipation

Methylnaltrexone (Relistor) for opioid-induced constipation 2010. DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation Content tools Share it Subcutaneous route instead of suppository or enema in terminal patients The use

2010 Drug and Therapeutics Bulletin of Navarre (Spain)

146. Prucalopride for the treatment of chronic constipation in women (TA211)

Prucalopride for the treatment of chronic constipation in women (TA211) Overview | Prucalopride for the treatment of chronic constipation in women | Guidance | NICE Prucalopride for the treatment of chronic constipation in women Technology appraisal guidance [TA211] Published date: 15 December 2010 Share Guidance on prucalopride (Resolor) for treating chronic constipation in women. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

147. New-onset constipation at acute stage after first stroke: incidence, risk factors, and impact on the stroke outcome (PubMed)

New-onset constipation at acute stage after first stroke: incidence, risk factors, and impact on the stroke outcome The prevalence of constipation after stroke varies from 30% to 60%. The incidence of new-onset constipation during the early stage of stroke remains uncertain. The present study was designed to investigate the prevalence of new-onset constipation, its risk factors, and its impact on stroke outcome in patients with their first stroke at acute stage.This is a prospective cohort (...) study of 154 patients admitted with their first stroke. New-onset constipation during the first 4 weeks of stroke was recorded, using the Rome II criteria for constipation. Demographics, characteristics of the stroke, laboratory parameters, and use of medications were evaluated as risk factors for constipation. Death, recurrent stroke, and handicap at 12 weeks were regarded as poor outcome. The impact of constipation on poor outcome was also studied.The cumulative incidence of new-onset constipation

Full Text available with Trip Pro

2009 EvidenceUpdates

148. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study (PubMed)

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL).A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist (...) , prucalopride, in patients with chronic constipation [or=3 SCBMs/week, averaged over 12 weeks. Other assessments included BM frequency, constipation-related QoL and symptoms and tolerability.Among 641 patients, significantly more patients taking prucalopride 2 or 4 mg (24%) than placebo (12%), achieved

Full Text available with Trip Pro

2009 EvidenceUpdates

149. Methylnaltrexone bromide - Constipation, Opioid-induced

Methylnaltrexone bromide - Constipation, Opioid-induced Common Drug Review CEDAC Meeting – November 19, 2008, CEDAC Reconsideration – January 21, 2009 Page 1 of 2 Notice of CEDAC Final Recommendation – January 28, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION METHYLNALTREXONE (Relistor ™ – Wyeth Canada) Description: Methylnaltrexone is a mu-opioid receptor antagonist approved by Health Canada for the treatment of opioid-induced constipation (...) outcome, was similar in the methylnaltrexone and placebo groups during the second week of the only two week study. Summary of Committee Considerations: The Committee considered a systematic review of two double-blind randomized controlled trials evaluating the effects of methylnaltrexone compared to placebo in palliative care patients taking other laxatives (n=287). The study population included many patients who did not report severe constipation at baseline and whose background regimens were

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

150. The use of naloxone for the treatment of opioid-induced constipation (OIC)

The use of naloxone for the treatment of opioid-induced constipation (OIC) "The use of naloxone for the treatment of opioid-induced constipation (" by Curtis Cole < > > > > > Title Author Date of Graduation 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Rob Rosenow PharmD, OD Second Advisor Annjanette Sommers MS, PAC Rights . Abstract Background: Opioid-induced constipation (OIC) is a major problem that can have a significant (...) impact on a patient’s quality of life (QoL). The use of opioids for both long and short term analgesia has been the standard treatment for many years. All opioids, like oxycodone, can be connected with the development of bowel dysfunction, with constipation being one of the more frequently reported adverse effects. Many of the standard methods and protocols that hospitals use seem to have little effect on this continuing problem. Hypothesis: That the use of oral naloxone Prolonged Release (PR

2009 Pacific University EBM Capstone Project

151. [Methylnaltrexone for opioid-induced constipation in cancer treatment]

[Methylnaltrexone for opioid-induced constipation in cancer treatment] Metylnaltrekson ved forstoppelse i kreftbehandling [Methylnaltrexone for opioid-induced constipation in cancer treatment] Metylnaltrekson ved forstoppelse i kreftbehandling [Methylnaltrexone for opioid-induced constipation in cancer treatment] Movik E, Ringerike T, Linnestad KK, Hofmann, B, Harboe I, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Movik E, Ringerike T, Linnestad KK, Hofmann, B, Harboe I, Klemp M. Metylnaltrekson ved forstoppelse i kreftbehandling. [Methylnaltrexone for opioid-induced constipation in cancer treatment] Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report from NOKC nr 23 - 2009.. 2009 Authors' conclusions Our review suggests that methylnaltrexone was more effective than placebo in terms of time to laxation

2009 Health Technology Assessment (HTA) Database.

152. Systematic review of Chinese herbal medicine for functional constipation

Systematic review of Chinese herbal medicine for functional constipation Systematic review of Chinese herbal medicine for functional constipation Systematic review of Chinese herbal medicine for functional constipation Cheng CW, Bian ZX, Wu TX CRD summary This review concluded that Chinese herbal medicine interventions or Chinese herbal medicines combined treatments showed benefit in the treatment of functional constipation when compared with cisapride, polyethylene glycol 4000, mosapride (...) , phenolphthalein, itopride and bifidobacteria alone, but not when compared with massage. The reliability of these conclusions is uncertain given the limited quality of included trials and other methodological concerns. Authors' objectives To assess the efficacy and safety of Chinese herbal medicine for the treatment of functional constipation. Searching The following databases were searched, without language restrictions, from 1994 to May 2009: MEDLINE, DARE, AMED, the Cochrane Library, ACP Journal Club

Full Text available with Trip Pro

2009 DARE.

153. Biofeedback therapy in fecal incontinence and constipation

Biofeedback therapy in fecal incontinence and constipation Biofeedback therapy in fecal incontinence and constipation Biofeedback therapy in fecal incontinence and constipation Enck P, van der Voort IR, Klosterhalfen S CRD summary The authors concluded that there was evidence of a substantial therapeutic effect of biofeedback therapy for constipation due to pelvic floor dyssynergia, but lack of evidence for biofeedback therapy for incontinence. There were a number of limitations to this review (...) . In particular, the review did not report data specific to pelvic floor dyssynergia, so these conclusions may not be reliable. Authors' objectives To evaluate the efficacy of biofeedback therapy for the treatment of constipation and faecal incontinence. Searching PubMed was searched for studies published in English between 1980 and 2008; search terms were reported. In addition, reference lists in identified articles, reviews and meta-analyses were screened. Study selection Randomised controlled trials (RCTs

2009 DARE.

154. Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited

Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limitedCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limitedCommentary Article Text Treatment Review

2009 Evidence-Based Nursing

155. Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures

Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment (...) and dietary measures Pijpers MA, Tabbers MM, Benninga MA, Berger MY CRD summary The review found that there was insufficient evidence to show that laxatives were superior to placebo for treating constipation in children and that no one laxative could be recommended over any other. Although the review was limited in some respects, in particular the failure to address statistical heterogeneity, the authors' cautious conclusions appear justified. Authors' objectives To determine the effectiveness

Full Text available with Trip Pro

2009 DARE.

156. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial (PubMed)

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial Though the greatest proportion of irritable bowel syndrome (IBS) patients report a mixed bowel pattern (IBS-Mixed), no available therapies have been rigorously evaluated in this subgroup. This study aimed to evaluate the efficacy and safety of the 5-HT(4) agonist tegaserod in women with IBS-Mixed and IBS with constipation (IBS-C).This prospective, double-blind, randomized

Full Text available with Trip Pro

2008 EvidenceUpdates

157. Methylnaltrexone for opioid-induced constipation in advanced illness. (PubMed)

Methylnaltrexone for opioid-induced constipation in advanced illness. Constipation is a distressing side effect of opioid treatment. As a quaternary amine, methylnaltrexone, a mu-opioid-receptor antagonist, has restricted ability to cross the blood-brain barrier. We investigated the safety and efficacy of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients with advanced illness.A total of 133 patients who had received opioids for 2 or more weeks and who had (...) received stable doses of opioids and laxatives for 3 or more days without relief of opioid-induced constipation were randomly assigned to receive subcutaneous methylnaltrexone (at a dose of 0.15 mg per kilogram of body weight) or placebo every other day for 2 weeks. Coprimary outcomes were laxation (defecation) within 4 hours after the first dose of the study drug and laxation within 4 hours after two or more of the first four doses. Patients who completed this phase were eligible to enter a 3-month

2008 NEJM

158. A placebo-controlled trial of prucalopride for severe chronic constipation. (PubMed)

A placebo-controlled trial of prucalopride for severe chronic constipation. In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation.In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once (...) efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment.Over 12 weeks, prucalopride significantly improved bowel function and reduced

2008 NEJM

159. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting (PubMed)

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting Relatively few pharmacological treatment options are available for treating patients with irritable bowel syndrome. New and effective medicines are urgently required.To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort (...) in patients with constipation-predominant irritable bowel syndrome.In this randomized, placebo-controlled, phase IIb study in the primary care setting, men and women were randomized to placebo or renzapride (1, 2 or 4 mg/day) for 12 weeks. The primary outcome measure was patient self-assessed relief of abdominal pain/discomfort during weeks 5-12. Secondary efficacy measures included patients' assessment of their bowel habits, stool consistency and quality of life.Although there were no statistically

Full Text available with Trip Pro

2008 EvidenceUpdates

160. Behavioral therapy for childhood constipation: a randomized, controlled trial (PubMed)

Behavioral therapy for childhood constipation: a randomized, controlled trial It has been suggested that the addition of behavioral interventions to laxative therapy improves continence in children with functional fecal incontinence associated with constipation. Our aim was to evaluate the clinical effectiveness of behavioral therapy with laxatives compared with conventional treatment in treating functional constipation in childhood.In this randomized, controlled trial conducted in a tertiary (...) hospital in The Netherlands, 134 children aged 4 to 18 years with functional constipation were randomly assigned to 22 weeks (12 visits) of either behavioral therapy or conventional treatment. Primary outcomes were defecation frequency, fecal incontinence frequency, and success rate. Success was defined as defecation frequency of > or = 3 times per week and fecal incontinence frequency of < or = 1 times per 2 weeks irrespective of laxative use. Secondary outcomes were stool-withholding behavior

Full Text available with Trip Pro

2008 EvidenceUpdates